Antibodies to cd40 and pharmaceutical compositions containing the same
Israel Patent
Stats

Importance
| IL Family Size
|
Non-US Coverage
|
Abstract
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
First Claim
Family
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations
Patent Owner(s)
| Patent Owner | Address |
|---|---|
| PFIZER PROD INC | USCONNECTICUT USA |
International Classification(s)
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C12P:FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESI....
- C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF
- A01K:ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; ....
- A01H:NEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT ....
- A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Inventor(s)
- No Inventor to display
Cited Art Landscape
- No Cited Art to Display
Full Text
Legal Events
Matter Detail
Update Public Data
Dismiss
Edit
Save
Renewals Detail
Edit
Save
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.